Advent Life Sciences

All figures cover the European funds tracked here since 1 January 2025, whether closed or still raising, and are compiled from public sources.

Tracked funds

1

Reported volume

€87m

Latest public closing

24 Sept 2026

Reported volume sums the public fund amounts tracked here, not the manager's firm-wide assets under management, so it may differ from totals on the manager's website.

London-based transatlantic venture investor building life-sciences companies in the UK, Europe and the US.

Focus: Early and mid-stage life sciences: therapeutics and drug discovery, enabling technologies and medical technology, from seed and Series A onward

18 February 2021: closed Fund III and the Advent-Harrington Impact Fund with $215m combined (company press release).